• AlzeCure completed its licensing and collaboration deal with QuantumCell for the NeuroRestore Alzheimer’s platform, including lead candidate ACD856.
• Transaction closed following receipt of the full upfront payment of USD 12 million under the July 1, 2026 agreement.
• Upfront comprises a USD 7 million cash license fee, a USD 5 million direct investment in AlzeCure.
• QuantumCell takes global rights, assumes responsibility for clinical development, handles commercialization of NeuroRestore.
• Deal includes milestones and tiered royalties; total value exceeds USD 2.2 billion excluding royalties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzeCure Pharma AB published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608120415ACCESSWRNAPR_____1206415) on August 12, 2026, and is solely responsible for the information contained therein.